Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Cut by US Bancorp DE
US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the ...
Arrowhead data supports blockbuster potential of ARO-C3, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...
ETF Daily News23d
Rhumbline Advisers Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
The institutional investor owned 380,344 shares of the biotechnology company’s stock after buying an additional 7,912 shares during the period. Rhumbline Advisers’ holdings in Arrowhead ...